Английская Википедия:Bemcentinib

Материал из Онлайн справочника
Версия от 22:38, 7 февраля 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Infobox drug | drug_name = | INN = | type =<!-- empty --> | IUPAC_name = 1-(6,7-Dihydro-5''H''-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-''N''-[(7''S'')-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5''H''-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine | image = Bemcentinib.svg | alt...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Infobox drug

Bemcentinib, also known as BGB324 or R428, is an experimental oral small molecule that is an inhibitor of AXL kinase.[1] Bemcentinib was licensed from Rigel Pharmaceuticals by BerGenBio and currently undergoing six Phase II trials in various solid and hematological tumors as monotherapy and in combination with immunotherapy, chemotherapy, and targeted therapeutics.

Function

Bemcentinib targets and binds to the intracellular catalytic kinase domain of AXL receptor tyrosine kinase and inhibits its activity. Increase in AXL function has been linked to key mechanisms of drug resistance and immune escape by tumor cells, leading to aggressive metastatic cancers.[2] In addition, BGB324 enhances sensitivity to various therapies including chemotherapy, immunotherapy and several targeted therapeutics.[3][4]

Clinical trials

Bemcentinib is currently undergoing Phase II clinical trials for non-small-cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), acute myeloid leukemia /myelodysplastic syndrome (AML/MDS), melanoma and metastatic pancreatic cancer.Шаблон:Cn

COVID-19

In April 2020 Bemcentinib became the first candidate to be selected as part of the UK Government's ACCORD (Accelerating COVID-19 Research & Development) for Phase II clinical trial in patients with COVID-19.[5]

References

Шаблон:Reflist

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ Шаблон:Cite web
  2. ↑ Gay, Carl M; Balaji, Kavitha; Byers, Lauren Averett (2017). "Giving AXL the axe: targeting AXL in human malignancy". British Journal of Cancer. 116 (4): 415–423.
  3. ↑ Шаблон:Cite book
  4. ↑ Шаблон:Cite journal
  5. ↑ Шаблон:Cite web
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Bemcentinib&oldid=13463151